Association of Parity with the Risks of Gestational Diabetes and Macrosomia: A Retrospective Cohort Study in Nanjing, China
CONCLUSION: Parity was not associated with GDM risk, but mildly associated with macrosomia risk. Particular attention should be paid to multiparae with advanced age to reduce the risks of GDM and macrosomia.PMID:38584550 | DOI:10.2174/0113816128294311240322041144 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 8, 2024 Category: Drugs & Pharmacology Authors: Shijie Geng Junya Wang Zhi Geng Juan Wen Source Type: research
Elucidation of the Molecular Mechanism of Compound Danshen Dripping Pills Against Angina Pectoris based on Network Pharmacology and Molecular Docking
CONCLUSION: This study comprehensively illustrated the bioactive, potential targets, and molecular mechanisms of CDDP against AP, offering fresh perspectives into the molecular mechanisms of CDDP in preventing and treating AP.PMID:38584551 | DOI:10.2174/0113816128287109240321074628 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 8, 2024 Category: Drugs & Pharmacology Authors: Xiaocui Tian Shiqi Yin Zhiguang Liu Jinglin Cao Xinyu Liu Qi Qiu Source Type: research
CRISPR and Gene Editing: A Game-Changer in Drug Development
Curr Pharm Des. 2024 Apr 4. doi: 10.2174/0113816128298080240328053845. Online ahead of print.ABSTRACTCRISPR and gene editing technologies have emerged as transformative tools in medicine, offering unprecedented precision in targeting genetic disorders and revolutionizing drug development. This review explores the multifaceted impact of CRISPR across various medical domains, from hereditary diseases to infectious diseases and cancer. The potential of CRISPR in personalized medicine, therapeutic innovation, and pandemic prevention is highlighted, along with its role in reshaping traditional drug development processes. Howeve...
Source: Current Pharmaceutical Design - April 8, 2024 Category: Drugs & Pharmacology Authors: Abhishek Verma Tarun Sharma Ankit Awasthi Source Type: research
Celastrol Elicits Antitumor Effects through Inducing Immunogenic Cell Death and Downregulating PD-L1 in ccRCC
CONCLUSION: These findings indicate that CeT not only induces ICD but also suppresses PD-L1 by down-regulating MAPK1 expression, which will provide an attractive strategy for ccRCC immunotherapy.PMID:38584553 | DOI:10.2174/0113816128288970240321073436 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 8, 2024 Category: Drugs & Pharmacology Authors: Hong-Fang Li Neng Zhu Jia-Jun Wu Ya-Ning Shi Jia Gu Li Qin Source Type: research
Neuropilin-1 Binding Peptide as Fusion to Diphtheria Toxin Induces Apoptosis in Non-small Cell Lung Cancer Cell Line
CONCLUSION: Taken together, DTA-triCRGDK is a promising tool for targeted therapy of NRP-1 overexpressing cancer cells.PMID:38584554 | DOI:10.2174/0113816128292382240325074032 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 8, 2024 Category: Drugs & Pharmacology Authors: Sara Eghtedari Mahdi Behdani Fatemeh Kazemi-Lomedasht Source Type: research
Network Pharmacology Study on Herb Pair Bletilla striata-Galla chinensis in the Treatment of Chronic Skin Ulcers
CONCLUSION: This study predicted the core targets and signal transduction pathways in the treatment of CSUs to provide a reference for further molecular mechanism research.PMID:38571354 | DOI:10.2174/0113816128288490240322055201 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 4, 2024 Category: Drugs & Pharmacology Authors: Yue Wang Tengteng Ding Xing Jiang Source Type: research
Survival of Patients with Primary Brain Tumor: A Data Analysis of 10 Years
CONCLUSION: This study draws attention to the variations in the median survival times of the various kinds of primary brain tumors, with oligodendroglioma having the longest median survival time (199 months, or approximately 16.6 years) and glioblastoma having the shortest (8 months).PMID:38571355 | DOI:10.2174/0113816128306113240328050608 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 4, 2024 Category: Drugs & Pharmacology Authors: Shristy Verma Rishabha Malviya Prerna Uniyal Source Type: research
Mechanism Research of PZD Inhibiting Lung Cancer Cell Proliferation, Invasion, and Migration Based on Network Pharmacology
CONCLUSION: PZD could inhibit the cell proliferation, migration, and invasion of NCI-H1299 cells partially through the PI3K/AKT signaling pathway. These findings suggested that PZD might be a potential treatment strategy for lung cancer patients.PMID:38571356 | DOI:10.2174/0113816128296328240329032332 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 4, 2024 Category: Drugs & Pharmacology Authors: Fan Feng Ping Hu Lei Peng Jun Chen Xingkui Tao Source Type: research
Network Pharmacology Study on Herb Pair Bletilla striata-Galla chinensis in the Treatment of Chronic Skin Ulcers
CONCLUSION: This study predicted the core targets and signal transduction pathways in the treatment of CSUs to provide a reference for further molecular mechanism research.PMID:38571354 | DOI:10.2174/0113816128288490240322055201 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 4, 2024 Category: Drugs & Pharmacology Authors: Yue Wang Tengteng Ding Xing Jiang Source Type: research
Survival of Patients with Primary Brain Tumor: A Data Analysis of 10 Years
CONCLUSION: This study draws attention to the variations in the median survival times of the various kinds of primary brain tumors, with oligodendroglioma having the longest median survival time (199 months, or approximately 16.6 years) and glioblastoma having the shortest (8 months).PMID:38571355 | DOI:10.2174/0113816128306113240328050608 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 4, 2024 Category: Drugs & Pharmacology Authors: Shristy Verma Rishabha Malviya Prerna Uniyal Source Type: research
Mechanism Research of PZD Inhibiting Lung Cancer Cell Proliferation, Invasion, and Migration Based on Network Pharmacology
CONCLUSION: PZD could inhibit the cell proliferation, migration, and invasion of NCI-H1299 cells partially through the PI3K/AKT signaling pathway. These findings suggested that PZD might be a potential treatment strategy for lung cancer patients.PMID:38571356 | DOI:10.2174/0113816128296328240329032332 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 4, 2024 Category: Drugs & Pharmacology Authors: Fan Feng Ping Hu Lei Peng Jun Chen Xingkui Tao Source Type: research
Network Pharmacology Study on Herb Pair Bletilla striata-Galla chinensis in the Treatment of Chronic Skin Ulcers
CONCLUSION: This study predicted the core targets and signal transduction pathways in the treatment of CSUs to provide a reference for further molecular mechanism research.PMID:38571354 | DOI:10.2174/0113816128288490240322055201 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 4, 2024 Category: Drugs & Pharmacology Authors: Yue Wang Tengteng Ding Xing Jiang Source Type: research
Survival of Patients with Primary Brain Tumor: A Data Analysis of 10 Years
CONCLUSION: This study draws attention to the variations in the median survival times of the various kinds of primary brain tumors, with oligodendroglioma having the longest median survival time (199 months, or approximately 16.6 years) and glioblastoma having the shortest (8 months).PMID:38571355 | DOI:10.2174/0113816128306113240328050608 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 4, 2024 Category: Drugs & Pharmacology Authors: Shristy Verma Rishabha Malviya Prerna Uniyal Source Type: research
Mechanism Research of PZD Inhibiting Lung Cancer Cell Proliferation, Invasion, and Migration Based on Network Pharmacology
CONCLUSION: PZD could inhibit the cell proliferation, migration, and invasion of NCI-H1299 cells partially through the PI3K/AKT signaling pathway. These findings suggested that PZD might be a potential treatment strategy for lung cancer patients.PMID:38571356 | DOI:10.2174/0113816128296328240329032332 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 4, 2024 Category: Drugs & Pharmacology Authors: Fan Feng Ping Hu Lei Peng Jun Chen Xingkui Tao Source Type: research
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?
This article aims to uncover the reasons for the confusion in the literature and to unravel why SGLT2i failed to succeed in COVID-19 based on some solid evidence as well as speculative and personal perspectives.PMID:38566383 | DOI:10.2174/0113816128300162240322075423 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 3, 2024 Category: Drugs & Pharmacology Authors: Medine Cumhur Cure Erkan Cure Source Type: research
